Table 2.
The prevalence of amplification of mutated EGFR gene fragment containing T790M mutation in CNS metastases of NSCLC
| Clinical measures | Prevalence of T790M mutation (<1 % of mutated DNA) | Prevalence of T790M mutation (1–0.1 % of mutated DNA) | Prevalence of T790M mutation (less than 0.1 % of mutated DNA) |
|---|---|---|---|
| Total cases (n = 143) | 25 (17.5 %) | 5 (3.5 %) | 20 (14 %) |
| NSCLC-NOS (n = 38) | 10 (26.4 %) | 2 (5.3 %) | 8 (21.1 %) |
| Adenocarcinoma (n = 61) | 8 (13.1 %) | 1 (1.6 %) | 7 (11.5 %) |
| Squamous cancer (n = 23) | 4 (17.4 %) | 0 | 4 (17.4 %) |
| Large-cell cancer (n = 21) | 3 (14.2 %) | 2 (9.5 %) | 1 (4.7 %) |
| Sex | |||
| Female (n = 44) | 9 (20.5 %) | 1 (2.3 %) | 8 (18.2 %) |
| Male (n = 99) | 16 (16.1 %) | 4 (4 %) | 12 (12.1 %) |
| Smoking status | |||
| Smokers (n = 86) | 17 (19.8 %) | 3 (3.5 %) | 14 (16.3 %) |
| Non-smokers (n = 32) | 4 (12.5 %) | 1 (3.1 %) | 3 (9.4 %) |
| Lack of data (n = 25) | 4 (16 %) | 0 | 4 (16 %) |